LIXTE Biotechnology Announced Publication Of Data In EMBO Reports Showing LB-100 Increases Recognition Of Colon Cancer Cells By Immune System
LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System
by Disrupting the Process of RNA Splicing